Document Type
Article
Version Deposited
Published Version
Publication Date
4-1-2024
Publication Title
Antibody Therapeutics
DOI
10.1093/abt/tbae006
Abstract
Thymic stromal lymphopoietin (TSLP) is a member of the IL-2 cytokine family and has been widely recognized as a master regulator of type 2 inflammatory responses at barrier surfaces. Recent studies found dysregulation of the TSLP-TSLP receptor (TSLPR) pathway is associated with the pathogenesis of not only allergic diseases but also a wide variety of cancers including both solid tumors and hematological tumors. Thus, the blockade of TSLP represents an attractive therapeutic strategy for allergic diseases and cancer. In this study, we report the development of a novel humanized anti-TSLP monoclonal antibody (mAb) HZ-1127. Binding affinity, specificity, and ability of HZ-1127 in inhibiting TSLP were tested. HZ-1127 selectively binds to the TSLP cytokine with high affinity and specificity. Furthermore, HZ-1127 dramatically inhibits TSLP-dependent STAT5 activation and is more potent than Tezepelumab, which is an FDA-approved humanized mAb against TSLP for severe asthma treatment in inhibiting TSLP-induced CCL17 and CCL22 chemokines secretion in human peripheral blood mononuclear cells. Our pre-clinical study demonstrates that HZ-1127 may serve as a potential therapeutic agent for allergic diseases and cancer.
Recommended Citation
Liu X, Han J, Wang Q, Wang P, Li L, Du K, Jiang F, Zhang P, Liu H, Huang J. Development of a novel humanized anti-TSLP monoclonal antibody HZ-1127 with anti-allergic diseases and cancer potential. Antib Ther. 2024 Feb 27;7(2):123-130. doi: 10.1093/abt/tbae006. PMID: 38566968; PMCID: PMC10983073.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Comments
© The Author(s) 2024. Published by Oxford University Press on behalf of Antibody Therapeutics.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License.